In the wake of Cronos group (NASDAQ:CRON; TSXV:CRON) becoming the first Canadian licensed producer (LP) to offer its common stock in the Nasdaq Global Market, a selection of fellow LPs have since announced their intentions to also join premier US stock exchanges soon enough.

Bruce Linton, CEO of Canopy Growth (TSX:WEED) said during a public event in early March that his company was already preparing for a Nasdaq listing when it became involved with an investment deal from alcohol producer Constellation Brands (NYSE:STZ).

The Nasdaq listing for cannabis companies will require these companies do not hold assets in the US that involve any physical interaction with marijuana.

“The Nasdaq is doing a great job not allowing people to list who break federal laws and that’s a place where we should list in due course,” Linton said.

As reported by the Financial Post, Beacon Security analyst Vahan Ajamian wrote in a note that he expected the Canopy US listing to take place in the second quarter of the 2018 fiscal year.

Not to be left behind, Aurora Cannabis (TSX:ACB; OTC:ACBFF), which already lists on the OTCQX Best Market, announced it is also exploring the option to offer its stock on other exchanges.

“We’ll look at all exchanges, we’ll look at New York Stock Exchange,” Terry Booth, CEO of Aurora told Bloomberg.

Cronos trying to showcase legal cannabis market

After launching its stock on the Nasdaq, Mike Gornstein, CEO of Cronos said the entire industry is trying to raise awareness of the burgeoning legal cannabis industry.

“We did have a number of investors we’d speak to in the US that would ask ‘is it even legal to invest in a Canadian cannabis company?’ And by listing on the Nasdaq we are able to help that,” Gornstein told BNN.

Gornstein added part of the company’s motive behind launching on the Nasdaq relates to the possibility of entering the US market once it becomes federally legal and attracting American investors ahead of time.

Cronos officially launched its Nasdaq stock on March 6. Since then its share price has gone down 10.99 percent. At market close on Monday (March 12) market closure, Cronos finished at $8.79 signifying a 5.63 decrease and a $0.53 loss per share.

Investor Takeaway

Spearheaded by Cronos, the move to offer stock in the premier US exchanges offers a chance at legitimacy for the entire cannabis industry and–as repeatedly explained by executives–the type of investors available on these exchanges.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less